Clinical MedicineIn-Press PreviewGeneticsOphthalmology Open Access | 10.1172/jci.insight.188216
1Department of Ophthalmology and Roger and Karalis Johnson Retina Center, University of Washington, Seattle, United States of America
2Division of Oncology, Seattle Children’s Hospital, Seattle, United States of America
3Division of Genetic Medicine, Seattle Children’s Hospital, Seattle, United States of America
4Fred Hutch Cancer Consortium, Seattle, United States of America
Find articles by Stacey, A. in: JCI | PubMed | Google Scholar
1Department of Ophthalmology and Roger and Karalis Johnson Retina Center, University of Washington, Seattle, United States of America
2Division of Oncology, Seattle Children’s Hospital, Seattle, United States of America
3Division of Genetic Medicine, Seattle Children’s Hospital, Seattle, United States of America
4Fred Hutch Cancer Consortium, Seattle, United States of America
Find articles by Nakamichi, K. in: JCI | PubMed | Google Scholar
1Department of Ophthalmology and Roger and Karalis Johnson Retina Center, University of Washington, Seattle, United States of America
2Division of Oncology, Seattle Children’s Hospital, Seattle, United States of America
3Division of Genetic Medicine, Seattle Children’s Hospital, Seattle, United States of America
4Fred Hutch Cancer Consortium, Seattle, United States of America
Find articles by Huey, J. in: JCI | PubMed | Google Scholar
1Department of Ophthalmology and Roger and Karalis Johnson Retina Center, University of Washington, Seattle, United States of America
2Division of Oncology, Seattle Children’s Hospital, Seattle, United States of America
3Division of Genetic Medicine, Seattle Children’s Hospital, Seattle, United States of America
4Fred Hutch Cancer Consortium, Seattle, United States of America
Find articles by Stevens, J. in: JCI | PubMed | Google Scholar
1Department of Ophthalmology and Roger and Karalis Johnson Retina Center, University of Washington, Seattle, United States of America
2Division of Oncology, Seattle Children’s Hospital, Seattle, United States of America
3Division of Genetic Medicine, Seattle Children’s Hospital, Seattle, United States of America
4Fred Hutch Cancer Consortium, Seattle, United States of America
Find articles by Waligorski, N. in: JCI | PubMed | Google Scholar
1Department of Ophthalmology and Roger and Karalis Johnson Retina Center, University of Washington, Seattle, United States of America
2Division of Oncology, Seattle Children’s Hospital, Seattle, United States of America
3Division of Genetic Medicine, Seattle Children’s Hospital, Seattle, United States of America
4Fred Hutch Cancer Consortium, Seattle, United States of America
Find articles by Crotty, E. in: JCI | PubMed | Google Scholar
1Department of Ophthalmology and Roger and Karalis Johnson Retina Center, University of Washington, Seattle, United States of America
2Division of Oncology, Seattle Children’s Hospital, Seattle, United States of America
3Division of Genetic Medicine, Seattle Children’s Hospital, Seattle, United States of America
4Fred Hutch Cancer Consortium, Seattle, United States of America
Find articles by Van Gelder, R. in: JCI | PubMed | Google Scholar |
1Department of Ophthalmology and Roger and Karalis Johnson Retina Center, University of Washington, Seattle, United States of America
2Division of Oncology, Seattle Children’s Hospital, Seattle, United States of America
3Division of Genetic Medicine, Seattle Children’s Hospital, Seattle, United States of America
4Fred Hutch Cancer Consortium, Seattle, United States of America
Find articles by Mustafi, D. in: JCI | PubMed | Google Scholar
Published December 26, 2024 - More info
BACKGROUND. Current clinical sequencing methods cannot effectively detect DNA methylation and allele-specific variation to provide parent-of-origin information from the proband alone. Parent-of-origin effects can lead to differential disease and the inability to assign this in de novo cases limits prognostication in the majority of affected individuals with retinoblastoma, a hereditary cancer with suspected parent-of-origin effects.
METHODS. To directly assign parent-of-origin in retinoblastoma patients, genomic DNA was extracted from blood samples for sequencing using a programmable, targeted single-molecule long-read DNA genomic and epigenomic approach. This allowed germline variant calling and simultaneous haplotype-resolved CpG methylation in subjects with familial (n=7) and de novo (n=9) retinoblastoma.
RESULTS. Targeted long-read sequencing allowed phasing genomic variation with a differentially methylated region in intron 2 of the RB1 gene to confirm parent-of-origin in known familial samples. Leveraging this approach allowed us to directly assign parent-of-origin rapidly in simple and complex de novo cases from the proband alone. The ability to assign parent-of-origin in all cases of retinoblastoma showed that harboring disease-causing variants on the paternally inherited allele, whether arising familial or de novo, is associated with more advanced cancer staging at presentation and significantly greater risk of chemotherapy failure (P=0.002).
CONCLUSION. This study demonstrates the diagnostic potential of multi-omic long-read profiling to unveil the parent-of-origin effect in hereditary cancer. The approach in this work will be instrumental in assigning parent-of-origin to other genetic diseases using local and distant imprinting signals in the genome.
FUNDING. National Eye Institute, NIH (K08EY033789); Gerber Foundation; Research to Prevent Blindness